Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62nd American Society of Hematology (ASH) Annual Meeting
Intended for investors and other interested audiences, the event includes presentations by
-
Sundar Jagannath , MD, Professor of Medicine, Hematology and Medical Oncology,Mount Sinai School of Medicine ; Director, Multiple Myeloma Program atMount Sinai Hospital . -
Thomas G. Martin , MD, Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, and Associate Director, Myeloma Program, UCSF; Co-Leader, Hematopoietic Malignancies Program,Helen Diller Family Comprehensive Cancer Center .
To register and to view the live webcast, please visit: LegendBiotechASH2020.Convene.com.
About CARTITUDE-1
Cilta-cel is currently being investigated in the Phase 1b/2 CARTITUDE-1 (MMY2001, NCT03548207) registration study conducted in the US and
About Cilta-cel
Cilta-cel is an investigational chimeric antigen receptor T (CAR-T) cell therapy, formerly identified as JNJ-4528 in the
About
Cautions Concerning Forward-Looking Statements
This information constitutes forward-looking statements relating to the business of Legend, including express or implied discussions regarding the clinical development of its product candidates and potential attributes and benefits of such product candidates. Such forward-looking statements reflect the current views of Legend’s management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, Legend’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; Legend’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing and other political pressures. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
The safety and efficacy of the product candidates and/or uses under investigation have not been established. There is no guarantee that the product candidates will receive health authority approval or become commercially available in any country for the uses being investigated.
The information in this press release speaks only as of the date hereof. Legend assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005327/en/
For Media and Investor Relations inquiries, please contact:
jessie.yeung@legendbiotech.com or investor@legendbiotech.com
Surabhi.verma@legendbiotech.com or media@legendbiotech.com
For Medical Affairs inquiries, please contact:
tonia.nesheiwat@legendbiotech.com or medicalinformation@legendbiotech.com
Source: